Managing Risk Management: FDA Wants To Gauge Effectiveness Of RiskMAPs
Executive Summary
FDA should evaluate the effectiveness of risk management plans, Office of Pharmacoepidemiology & Statistical Science Director Paul Seligman said
You may also be interested in...
PDUFA IV Negotiations Underway With FDA, Industry Working In Harmony
PhRMA will pursue earlier postmarketing commitment negotiations with FDA as part of a limited industry agenda for the third reauthorization of the Prescription Drug User Fee Act
PDUFA IV Negotiations Underway With FDA, Industry Working In Harmony
PhRMA will pursue earlier postmarketing commitment negotiations with FDA as part of a limited industry agenda for the third reauthorization of the Prescription Drug User Fee Act
BIO’s Evergreening Project: CEO Greenwood Discusses Cost-Effectiveness And The “Inevitability” Of Follow-On Biologics
James Greenwood joined the Biotechnology Industry Organization as president and CEO in January 2005 after 12 years in Congress. His priorities early on were to prevent drug safety worries from slowing approvals and to ensure the quality of BIO as an advocacy organization. Editors from "The Pink Sheet" spoke with Greenwood earlier this year about the challenges and opportunities facing the biotechnology industry in 2006.